External Validation of Generic and Cancer-Specific Risk Stratification Tools in Patients With Pulmonary Embolism and...

Area of Science:

• Oncology
• Pulmonology
• Cardiology

Background:

• Existing risk stratification tools for pulmonary embolism (PE) mortality often lack specificity for cancer patients.
• Active cancer is a significant risk factor influencing PE outcomes.
• There is a need for validated tools to accurately assess PE risk in oncology patients.

Purpose of the Study:

• To evaluate the performance of cancer-specific and generic risk stratification tools in predicting 30-day mortality in patients with active cancer and PE.
• To compare the prognostic accuracy of tools like RIETE, POMPE-C, Font criteria, Hestia, PESI, and GPS in this specific population.

Main Methods:

• A retrospective analysis of 124 adult patients with objectively confirmed PE and active cancer.
• Calculation of risk categories (low/high) using six different risk stratification tools.
• Determination of the accuracy (sensitivity and specificity) of each tool for predicting 30-day all-cause mortality.

Main Results:

• Twenty-five patients (20.2%) died within 30 days of PE diagnosis.
• Cancer-specific tools (POMPE-C, RIETE, Font criteria) showed higher sensitivity (88.0%-96.0%) and better low-risk patient identification (32%-43%) compared to generic tools.
• Generic tools like PESI and Hestia had high sensitivity but low specificity and identified fewer low-risk patients.

Conclusions:

• Cancer-specific risk stratification tools demonstrate superior prognostic accuracy for 30-day mortality in patients with active cancer and PE.
• POMPE-C, RIETE, and Font criteria are recommended for risk assessment in this population due to their ability to identify more survivors.
• These findings support the use of tailored risk assessment strategies for PE management in cancer patients.